David Mischoulon, MD PhD, is the Director of the Depression Clinical and Research Program at Massachusetts General Hospital andJoyce R. Tedlow Professor of Psychiatryat Harvard Medical School. He is also the Director of Training at the MGH Clinical Trials Network & Institute (CTNI). His research has emphasized depression, especially exploration of complementary and alternative medicine (CAM) approaches and psychopharmacology for the treatment of depression.
-
Depression rates in the U.S. have climbed steadily, with more than 18% of adults now reporting symptoms or treatment—nearly double the level from a decade […] -
By targeting inflammation, omega-3s may enhance the efficacy of traditional antidepressants and improve outcomes for patients who have not responded well to conventional therapies. -
Artificial intelligence may be able to use data passively collected from wearable devices and smartphones to improve mental health care by providing real-time updates to […] -
Whole-body hyperthermia is emerging as a promising new treatment for major depressive disorder. But how does it work? -
This exploratory clinical trial indicates that higher doses of omega-3 fatty acids improves motivational symptoms and cognition in depressed individuals exhibiting a pro-inflammatory phenotype. -
In adults with moderate to severe depression, heated yoga sessions delivered over an 8 week period were associated with clinically significant reductions in depressive symptoms.